8-K: Neumora Initiates Phase 1 Study for NMRA-898 Schizophrenia Drug

Neumora Therapeutics announced the initiation of a Phase 1 clinical study for NMRA-898, its second M4 positive allosteric modulator for neuropsychiatric disorders.

Summary

• Neumora Therapeutics, Inc. initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898.
• NMRA-898 is an investigational M4 muscarinic receptor positive allosteric modulator (PAM) intended for schizophrenia and other neuropsychiatric disorders.
• This is the second M4 PAM in Neumora's M4 franchise, alongside NMRA-861, which began its Phase 1 SAD/MAD study in July 2025.
• Both studies will evaluate safety, tolerability, and human pharmacokinetic data to confirm the potential for once-daily dosing and central nervous system exposure.
• Neumora plans to evaluate the strategy for its M4 franchise based on these data, potentially advancing development of one or both programs.
• NMRA-898 is structurally distinct from NMRA-861 and has demonstrated a best-in-class pre-clinical profile, with no convulsions observed in pre-clinical studies across multiple species, including rabbits.
• Neumora exclusively licensed intellectual property rights for NMRA-898 from the Warren Center for Neuroscience Drug Discovery at Vanderbilt University, including a composition of matter patent extending to 2044 (excluding any patent term adjustment or extension).
• Schizophrenia impacts approximately 3 million adults in the United States, with significant unmet medical need due to side effects and inefficacy of currently approved therapies.

Sentiment

Score: 7

Explanation: The initiation of a new Phase 1 clinical trial for a second M4 PAM is a positive development, expanding the pipeline and offering strategic flexibility. The pre-clinical safety profile (no convulsions) is encouraging. However, it's still very early stage, and significant risks remain in clinical development.

Positives

• Initiation of a Phase 1 study for NMRA-898 expands the company's clinical pipeline with a second M4 PAM.
• The M4 franchise now includes two distinct compounds, NMRA-861 and NMRA-898, offering strategic flexibility and potential best-in-class pharmacology.
• Pre-clinical studies of NMRA-898 showed no convulsions in multiple species, suggesting a potentially improved safety profile.
• NMRA-898 benefits from a composition of matter patent extending to 2044, providing long-term intellectual property protection.
• Targeting the M4 muscarinic receptor offers a promising approach to treating schizophrenia, potentially avoiding the serious side effects associated with current D2 dopamine receptor blockers.

Negatives

• No immediate financial results or revenue-generating milestones were announced.
• Clinical trials are inherently risky, and there is no guarantee of success for NMRA-898 or NMRA-861.
• The company plans to evaluate the strategy for its M4 franchise based on data, implying that one or both programs might not advance to later stages.

Risks

• Inherent uncertainty of clinical drug development and the unpredictability and lengthy process for obtaining regulatory approvals.
• Risks related to the timely initiation and enrollment in clinical trials.
• Reliance on third parties, including contract research organizations.
• Potential for serious or undesirable side effects of therapeutic candidates.
• Risks related to the ability to utilize and protect intellectual property rights.
• Sufficiency of capital resources to fund operations.

Future Outlook

Neumora plans to evaluate the strategy for its M4 franchise, potentially advancing development of one or both programs, and expects to provide a comprehensive franchise update by mid-2026. The company aims to redefine neuroscience drug development by bringing forward novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Management Comments

• "With both NMRA-898 and NMRA-861 now in the clinic, we are positioned with exceptional strategic flexibility as we advance two potentially best-in-class M4 PAMs." Bill Aurora, Pharm.D., chief operating and development officer, Neumora.
• "These structurally distinct M4 compounds each demonstrate potential best-in-class pharmacology, giving us the optionality to pursue one or both assets as we advance development. This not only strengthens our pipeline but also enables us to strategically prioritize indications where we can deliver the greatest impact for patients." Bill Aurora.

Industry Context

The announcement highlights a growing industry trend towards targeting M4 muscarinic receptors for neuropsychiatric disorders like schizophrenia, offering an alternative to traditional D2 dopamine receptor blockers which are often associated with significant side effects. This approach aims to address the high discontinuation rates of current antipsychotics due to inefficacy or intolerable side effects, positioning Neumora at the forefront of developing potentially safer and more effective treatments.

Stakeholder Impact

• Shareholders: Potential for increased long-term value if clinical trials are successful, but also exposure to early-stage drug development risks.
• Patients (Schizophrenia): Potential for new, improved treatment options with better safety profiles than existing therapies.
• Employees: Continued employment and potential for growth within a company advancing its pipeline.
• Vanderbilt University (Warren Center): Continued collaboration and potential for royalties from licensed intellectual property.

Next Steps

• Evaluate safety, tolerability, and human pharmacokinetic data for NMRA-898 (and NMRA-861) in Phase 1 SAD/MAD studies.
• Confirm potential for once-daily dosing and central nervous system exposure for both compounds.
• Evaluate the strategy for the M4 franchise based on Phase 1 data, potentially advancing one or both programs.
• Provide a comprehensive M4 franchise update by mid-2026.

Key Dates

Recommendation

The initiation of a Phase 1 study for NMRA-898 is a positive step, expanding Neumora's pipeline and demonstrating progress in its M4 franchise. The pre-clinical data, particularly the absence of convulsions, is encouraging. However, this is a very early-stage clinical program, and success in Phase 1 does not guarantee future success. The company also has another M4 PAM (NMRA-861) in Phase 1, and the strategy for advancing one or both will be determined later. Given the early stage and inherent risks of drug development, a 'hold' recommendation is appropriate for investors to monitor further clinical data and strategic decisions before making a more definitive investment move.

Keywords

Neumora Therapeutics, NMRA-898, Phase 1 Clinical Trial, M4 PAM, Schizophrenia, Neuroscience, Drug Development, Biopharmaceutical, Clinical-stage, NMRA-861